Blocking the Proliferation of B-cells in Leukemia

Blocking the Proliferation of B-cells in Leukemia
Chronic Lymphocytic Leukemia (CLL) is a malignant disease caused by uncontrolled proliferation of B-cells, a type of white blood cells. The high proliferation rate is due to blockage of the cells’ self destruction mechanism called apoptosis, which allows the cells to multiply in high levels. A group of scientists from Israel and the USA, headed by Professor Idit Shachar from the Weizmann Institute in Israel, found a way to overcome this blockage and allow the B-cells to achieve apoptosis. This new development may allow us to discontinue the proliferation of CLL in the body, and is now pending clinical trials.
Acute Myelogenous Leukemia (Credit: University of Virginia)
Acute Myelogenous Leukemia
(Credit: University of Virginia)

Like other kinds of leukemia, CLL is a cancer in the white blood cells. CLL affects a particular type of white blood cells: B-cells. Normally, the B-cells fight infections, but the cancerous B-cells lose this ability due to DNA mutations. Moreover, the mutations cause these B-cells to proliferate without control and they crowd out the healthy B-cells. The majority of CLL patients are males, and it is considered to be a disease of the elderly since it is rarely encountered in individuals under the age of 40. The disease is treated according to its severity in a specific patient, mainly by chemotherapy. This scientific achievement introduces a new therapeutic pathway.

The research suggests that a receptor protein located on the B-cells’ membrane is responsible for their ‘immortality’ (the subjugation of their apoptosis). The protein, named CD74, was previously found to be more active in CLL B-cells than in normal B-cells. The scientists hypothesized that it regulates the survival of the B-cells and that by having large amounts of it the cells eventually become ‘immortal’. Another fact that supports this hypothesis is that the CD74 needs to bind a small protein in order to activate its “lifesaving” mechanism, and this other protein was also found in high levels in CLL B-cells. The scientists assumed that blocking the binding of these two proteins will prevent them from activating the anti-apoptotic mechanism.

Using antibodies to disable the receptor protein CD74 from binding with the other protein, the scientists achieved a soaring mortality rate of CLL B-cells. The antibodies used in the experiment are produced by the New Jersey based Immunomedics company. Up to now, the antibodies were being tested against several types of leukemia without a full understanding of the mechanism. Now that the mechanism is known, clinical trials for CLL are being planned by Immunomedics. According to Professor Shachar: “Blocking the receptor or other stages in the pathway they activate might be a winning tactic, in the future, in the war against cancers involving B cells.”

More information can be found on the Weizmann Institute website.

Share This
Don't be shellfish...Share on Facebook0Tweet about this on Twitter0Share on Google+0Share on StumbleUpon0Digg thisShare on Reddit0Email this to someone

About the author

Asaf Peer

Asaf has a bachelor's degree in computer science and computational biology from the Hebrew University in Jerusalem. At the time being asaf is working towards his graduate degree in the same program.

View all articles by Asaf Peer